Discovery of potent broad spectrum antivirals derived from marine actinobacteria

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Raveh, Avi ^a   Delekta, Phillip C ^b   Dobry, Craig J ^b   Peng, Weiping ^b   Schultz, Pamela J ^a   Blakely, Pennelope K ^b   Tai, Andrew W ^b   Matainaho, Teatulohi ^c   Irani, David N ^b   Sherman, David H ^a,b   Miller, David J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PAPUA NEW GUINEA   (Papua New Guinea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCIN A1; PYRIMIDINE;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BUNYAVIRUS; CELL FRACTIONATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG ISOLATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; FEMALE; FLAVIVIRUS; LD 50; MITOCHONDRIAL ENERGY TRANSFER; MOUSE; NONHUMAN; ORGANISMS BY GEOGRAPHICAL DISTRIBUTION; PAPUA NEW GUINEA; PARAMYXOVIRUS; PHENOTYPIC VARIATION; PICORNAVIRUS; REPLICON; SEDIMENT; STREPTOMYCES; STREPTOMYCES KAVIENGENSIS; TOGAVIRUS; TRANSCRIPTION INITIATION; VALIDATION PROCESS; VIRUS CULTURE; VIRUS TITRATION; WESTERN EQUINE ENCEPHALITIS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ACTINOBACTERIA; ANIMALS; ANTIMYCIN A; ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CELL LINE; CENTRAL NERVOUS SYSTEM; CHEMICAL FRACTIONATION; ELECTRON TRANSPORT; ENCEPHALITIS VIRUSES; ENCEPHALITIS, ARBOVIRUS; GEOLOGIC SEDIMENTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MITOCHONDRIA; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; STREPTOMYCES; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 84891924279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082318     Document Type: Article

References (76)

1. Weaver SC, Reisen WK (2010) Present and future arboviral threats. Antiviral Res 85: 328-345. doi:10.1016/j.antiviral.2009.10.008. PubMed: 19857523.
2. Enserink M (2007) Infectious diseases. Chikungunya: no longer a third world disease. Science 318: 1860-1861. doi:10.1126/science. 318.5858.1860. PubMed: 18096785.
3. Nash D, Mostashari F, Fine A, Miller J, O'Leary D et al. (2001) The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344: 1807-1814. doi:10.1056/NEJM200106143442401. PubMed: 11407341. (Pubitemid 32538693)
4. Griffin DE (2001) Alphaviruses. In: DM Knipe, PM Howley, DE Griffin, RA Lamb, MA Martin. Fields Virology. fourth ed. Philadelphia: Lippincott Williams & Wilkins. pp. 917-962.
5. Aguilar MJ (1970) Pathological changes in brain and other target organs of infant and weanling mice after infection with nonneuroadapted western equine encephalitis virus. Infect Immun 2: 533-542. PubMed: 16557874.
6. Zlotnik I, Peacock S, Grant DP, Batter-Hatton D (1972) The pathogenesis of western equine encephalitis virus (WEE) in adult hamsters with special reference to the long and short term effects on the CNS of the attenuated clone 15 variant. Br J Exp Pathol 53: 59-77. PubMed: 5014245.
7. Liu C, Voth DW, Rodina P, Shauf LR, Gonzalez G (1970) A comparative study of the pathogenesis of western equine and eastern equine encephalomyelitis viral infections in mice by intracerebral and subcutaneous inoculations. J Infect Dis 122: 53-63. doi:10.1093/infdis/ 122.1-2.53. PubMed: 4914943.
8. Steele KE, Twenhafel NA (2010) REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol 47: 790-805. doi: 10.1177/ 0300985810372508. PubMed: 20551475.
9. Deresiewicz RL, Thaler SJ, Hsu L, Zamani AA (1997) Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med 336: 1867-1874. doi:10.1056/NEJM199706263362604. PubMed: 9197215. (Pubitemid 27263974)
10. Earnest MP, Goolishian HA, Calverley JR, Hayes RO, Hill HR (1971) Neurologic, intellectual, and psychologic sequelae following western encephalitis. A follow-up study of 35 cases. Neurology 21: 969-974. doi:10.1212/WNL.21.9.969. PubMed: 5106260.
11. Wolfe DN, Florence W, Bryant P (2013) Current biodefense vaccine programs and challenges. Hum Vaccin Immunother 9: 1-7. doi: 10.4161/hv.23606. PubMed: 23442580.
12. Bronze MS, Greenfield RA (2003) Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr Opin Investig Drugs 4: 172-178. PubMed: 12669378. (Pubitemid 36383013)
13. Sindac JA, Yestrepsky BD, Barraza SJ, Bolduc KL, Blakely PK et al. (2012) Novel inhibitors of neurotropic alphavirus replication that improve host survival in a mouse model of acute viral encephalitis. J Med Chem 55: 3535-3545. doi:10.1021/jm300214e. PubMed: 22428985.
14. Li Y, Wang L, Li S, Chen X, Shen Y et al. (2007) Seco-pregnane steroids target the subgenomic RNA of alphavirus-like RNA viruses. Proc Natl Acad Sci U S A 104: 8083-8088. doi:10.1073/pnas. 0702398104. PubMed: 17470783. (Pubitemid 47185879)
15. Julander JG, Smee DF, Morrey JD, Furuta Y (2009) Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 82: 169-171. doi:10.1016/j.antiviral.2009.02.201. PubMed: 19428608.
16. Julander JG, Bowen RA, Rao JR, Day C, Shafer K et al. (2008) Treatment of Venezuelan equine encephalitis virus infection with (-)- carbodine. Antiviral Res 80: 309-315. doi:10.1016/j.antiviral. 2008.07.002. PubMed: 18675850.
17. Reichert E, Clase A, Bacetty A, Larsen J (2009) Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur Bioterror 7: 413-427. doi:10.1089/bsp.2009.0032. PubMed: 20028250.
18. Peng W, Peltier DC, Larsen MJ, Kirchhoff PD, Larsen SD et al. (2009) Identification of thieno[3,2-b]pyrrole derivatives as novel small molecule inhibitors of neurotropic alphaviruses. J Infect Dis 199: 950-957. doi: 10.1086/597275. PubMed: 19239364.
19. Thompson LA, Ellman JA (1996) Synthesis and applications of small molecule libraries. Chem Rev 96: 555-600. doi:10.1021/cr9402081. PubMed: 11848765. (Pubitemid 126637733)
20. Dobson CM (2004) Chemical space and biology. Nature 432: 824-828. doi:10.1038/nature03192. PubMed: 15602547. (Pubitemid 40037137)
21. Schneider G, Fechner U (2005) Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 4: 649-663. doi:10.1038/ nrd1799. PubMed: 16056391. (Pubitemid 41149759)
22. Lipinski C, Hopkins A (2004) Navigating chemical space for biology and medicine. Nature 432: 855-861. doi:10.1038/nature03193. PubMed: 15602551. (Pubitemid 40037141)
23. Verdine GL (1996) The combinatorial chemistry of nature. Nature 384: 11-13. doi:10.1038/384011a0. PubMed: 8895593. (Pubitemid 26374532)
24. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75: 311-335. doi:10.1021/np200906s. PubMed: 22316239.
25. Walsh CT (2004) Polyketide and nonribosomal peptide antibiotics: modularity and versatility. Science 303: 1805-1810. doi:10.1126/ science.1094318. PubMed: 15031493. (Pubitemid 38374864)
26. Bhatnagar I, Kim SK (2012) Pharmacologically prospective antibiotic agents and their sources: a marine microbial perspective. Environ Toxicol Pharmacol 34: 631-643. doi:10.1016/j.etap.2012.08.016. PubMed: 23121870.
27. Gerwick WH, Fenner AM (2013) Drug discovery from marine microbes. Microb Ecol 65: 800-806. doi:10.1007/s00248-012-0169-9. PubMed: 23274881.
28. Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W et al. (2010) The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 31: 255-265. doi:10.1016/j.tips.2010.02.005. PubMed: 20363514.
29. Manivasagan P, Venkatesan J, Sivakumar K, Kim SK (2013) Marine actinobacterial metabolites: Current status and future perspectives. Microbiol Res 168: 311-332. doi:10.1016/j.micres.2013.02.002. PubMed: 23480961.
30. Magarvey NA, Keller JM, Bernan V, Dworkin M, Sherman DH (2004) Isolation and characterization of novel marine-derived actinomycete taxa rich in bioactive metabolites. Appl Environ Microbiol 70: 7520-7529. doi:10.1128/AEM.70.12.7520- 7529.2004. PubMed: 15574955. (Pubitemid 39643819)
31. Malinoski F, Stollar V (1981) Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110: 281-289. doi:10.1016/0042-6822(81)90060-X. PubMed: 6111860.
32. Dushee BR, Leben C, Keitt CW, Strong FM (1949) The isolation and properties of antimycin A. J Am Chem Soc 71: 2436-2437. doi:10.1021/ ja01175a057.
33. Hosotani N, Kumagai K, Nakagawa H, Shimatani T, Saji I (2005) Antimycins A10∼A16, seven new antimycin antibiotics produced by Streptomyces spp. SPA-10191 and SPA-8893. J Antibiot (Tokyo) 58: 460-467. (Pubitemid 41206461)
34. Xu LY, Quan XS, Wang C, Sheng HF, Zhou GX et al. (2011) Antimycins A(19) and A(20), two new antimycins produced by marine actinomycete Streptomyces antibioticus H74-18. J Antibiot (Tokyo) 64: 661-665. doi:10.1038/ja.2011.65. PubMed: 21847131.
35. Seipke RF, Barke J, Brearley C, Hill L, Yu DW et al. (2011) A single Streptomyces symbiont makes multiple antifungals to support the fungus farming ant Acromyrmex octospinosus. PLOS ONE 6: e22028. doi:10.1371/journal.pone. 0022028. PubMed: 21857911.
36. Karuppannan AK, Wu KX, Qiang J, Chu JJ, Kwang J (2012) Natural compounds inhibiting the replication of porcine reproductive and respiratory syndrome virus. Antiviral Res 94: 188-194. doi:10.1016/ j.antiviral.2012.03.008. PubMed: 22487208.
37. Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C et al. (2010) Highcontent assay to identify inhibitors of dengue virus infection. Assay Drug Dev Technol 8: 553-570. doi:10.1089/adt.2010.0321. PubMed: 20973722.
38. Hui EK, Nayak DP (2001) Role of ATP in influenza virus budding. Virology 290: 329-341. doi:10.1006/viro.2001.1181. PubMed: 11883197. (Pubitemid 33141234)
39. Trumpower BL (1990) The protonmotive Q cycle. Energy transduction by coupling of proton translocation to electron transfer by the cytochrome bc1 complex. J Biol Chem 265: 11409-11412. PubMed: 2164001.
40. Lennon RE (1973) Antimycin A, a piscicidal antibiotic. Adv Appl Microbiol 16: 55-96. doi:10.1016/S0065-2164(08)70023-6. PubMed: 4584680.
41. Bianchi TI, Avilés G, Sabattini MS (1997) Biological characteristics of an enzootic subtype of western equine encephalomyelitis virus from Argentina. Acta Virol 41: 13-20. PubMed: 9199709. (Pubitemid 27462795)
42. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J et al. (2001) Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3: 183-191. doi:10.1038/35055095. PubMed: 11175751. (Pubitemid 32118372)
43. Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM et al. (2005) Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. Cancer Chemother Pharmacol 56: 291-298. doi:10.1007/s00280-004-0978-8. PubMed: 15883820. (Pubitemid 40941800)
44. Tokutake N, Miyoshi H, Satoh T, Hatano T, Iwamura H (1994) Structural factors of antimycin A molecule required for inhibitory action. Biochim Biophys Acta 1185: 271-278. doi: 10.1016/0005-2728(94)90241-0. PubMed: 8180232. (Pubitemid 24157961)
45. Miyoshi H, Tokutake N, Imaeda Y, Akagi T, Iwamura H (1995) A model of antimycin A binding based on structure-activity studies of synthetic antimycin A analogues. Biochim Biophys Acta 1229: 149-154. doi: 10.1016/0005-2728(94)00185- 8. PubMed: 7727495.
46. Park WH, Han YW, Kim SH, Kim SZ (2007) An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J Cell Biochem 102: 98-109. doi:10.1002/jcb.21280. PubMed: 17372917.
47. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681. doi:10.1124/pr. 58.3.10. PubMed: 16968952.
48. Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem J 417: 1-13. doi:10.1042/BJ20082215. PubMed: 19061483.
49. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE (2009) Mitochondria and reactive oxygen species. Free Radic Biol Med 47: 333-343. doi:10.1016/j.freeradbiomed.2009.05.004. PubMed: 19427899.
50. Brennan JP, Southworth R, Medina RA, Davidson SM, Duchen MR et al. (2006) Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation. Cardiovasc Res 72: 313-321. doi:10.1016/ j.cardiores.2006.07.019. PubMed: 16950237. (Pubitemid 44511914)
51. Tahara EB, Navarete FD, Kowaltowski AJ (2009) Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic Biol Med 46: 1283-1297. doi:10.1016/ j.freeradbiomed. 2009.02.008. PubMed: 19245829.
52. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML (2011) Broadspectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108: 5777-5782. doi:10.1073/pnas. 1101143108. PubMed: 21436031.
53. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A et al. (2011) Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85: 6548-6556. doi:10.1128/JVI.02510-10. PubMed: 21507975.
54. Leyssen P, Balzarini J, De Clercq E, Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79: 1943-1947. doi:10.1128/JVI. 79.3.1943-1947.2005. PubMed: 15650220. (Pubitemid 40459141)
55. Löffler M, Jöckel J, Schuster G, Becker C (1997) Dihydroorotateubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem 174: 125-129. doi:10.1023/A: 1006859115450. PubMed: 9309676. (Pubitemid 27404179)
56. Schoepp RJ, Smith JF, Parker MD (2002) Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 302: 299-309. doi:10.1006/viro.2002.1677. PubMed: 12441074. (Pubitemid 35373858)
57. Herr F, Greselin E, Chappel C (1967) Toxicology studies of antimycin, a fish eradicant. Trans Am Fish Soc 96: 320-326. Available online at: doi:10.1577/1548-8659(1967)96[320:TSOAAF]2.0.CO;2
58. Hamilton PB, Carroll FI, Rutledge JH, Mason JE, Harris BS et al. (1969) Simple isolation of antimycin A1 and some of its toxicological properties. Appl Microbiol 17: 102-105. PubMed: 5774751.
59. Mayer AM, Rodríguez AD, Berlinck RG, Hamann MT (2007) Marine pharmacology in 2003-4: marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 145: 553-581. doi:10.1016/j.cbpc.2007.01.015. PubMed: 17392033. (Pubitemid 46660746)
60. Mayer AM, Rodríguez AD, Berlinck RG, Hamann MT (2009) Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim Biophys Acta 1790: 283-308. doi: 10.1016/j.bbagen.2009.03.011. PubMed: 19303911.
61. Mayer AM, Rodríguez AD, Berlinck RG, Fusetani N (2011) Marine pharmacology in 2007-8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 153: 191-222. doi:10.1016/ j.cbpc.2010.08.008. PubMed: 20826228.
62. Sabini MC, Escobar FM, Tonn CE, Zanon SM, Contigiani MS et al. (2012) Evaluation of antiviral activity of aqueous extracts from Achyrocline satureioides against western equine encephalitis virus. Nat Prod Res 26: 405-415. doi:10.1080/14786419.2010.490216. PubMed: 20623427.
63. Lin K, Gallay P (2013) Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Res 99: 68-77. doi:10.1016/ j.antiviral.2013.03.020. PubMed: 23578729.
64. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10: 507-519. doi:10.1038/nrd3480. PubMed: 21701501.
65. Ma X, Jin M, Cai Y, Xia H, Long K et al. (2011) Mitochondrial electron transport chain complex III is required for antimycin A to inhibit autophagy. Chem. Biol 18: 1474-1481.
66. Dreux M, Chisari FV (2010) Viruses and the autophagy machinery. Cell Cycle 9: 1295-1307. PubMed: 20305376.
67. Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T et al. (2012) Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome. RNA - PLOS Pathog 8: e1002561.
68. Rodrigues T, Lopes F, Moreira R (2010) Inhibitors of the mitochondrial electron transport chain and de novo pyrimidine biosynthesis as antimalarials: The present status. Curr Med Chem 17: 929-956. doi: 10.2174/092986710790820660. PubMed: 20156168.
69. Rohlena J, Dong LF, Ralph SJ, Neuzil J (2011) Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid Redox Signal 15: 2951-2974. doi:10.1089/ars.2011.3990. PubMed: 21777145.
70. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN et al. (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 82: 7096-7100. doi:10.1073/pnas.82.20.7096. PubMed: 2413459. (Pubitemid 16209699)
71. Horwitz JP, Chua J, Noel M (1964) Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl) thymine. J Org Chem 29: 2076-2078. doi:10.1021/jo01030a546.
72. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS et al. (2013) Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 30: 108-160. doi:10.1039/c2np20085f. PubMed: 23165928.
73. Castorena KM, Peltier DC, Peng W, Miller DJ (2008) Maturationdependent responses of human neuronal cells to western equine encephalitis virus infection and type I interferons. Virology 372: 208-220. doi:10.1016/j.virol.2007.10.025. PubMed: 18022665. (Pubitemid 351215467)
74. Peltier DC, Simms A, Farmer JR, Miller DJ (2010) Human neuronal cells possess functional cytoplasmic and TLR-mediated innate immune pathways influenced by phosphatidylinositol-3 kinase signaling. J Immunol 184: 7010-7021. doi:10.4049/jimmunol.0904133. PubMed: 20483728.
75. Peltier DC, Lazear HM, Farmer JR, Diamond MS, Miller DJ (2013) Neurotropic arboviruses induce interferon regulatory factor 3-mediated neuronal responses that are cytoprotective, interferon independent, and inhibited by western equine encephalitis virus capsid. J Virol 87: 1821-1833. doi:10.1128/JVI.02858-12. PubMed: 23192868.
76. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K et al. (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329: 1350-1359. doi:10.1016/j.bbrc. 2005.02.138. PubMed: 15766575. (Pubitemid 40568718)